Clinical Trials Browser

NCT03392246 2026-01-22

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Phase 2 Active not recruiting

25 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03581487 2025-11-05

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Phase 1/2 Completed

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

423 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT02117167 2024-01-10

SAFIR02_Lung

Phase 2 Completed

999 enrolled

Thoracic

Non-small Cell Lung Cancer Metastatic

NCT02503358 2023-03-21

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Phase 1 Completed

23 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01146756 2023-02-15

MEKRT

Phase 1 Completed

21 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01248247 2022-01-12

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

334 enrolled 14 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01586624 2021-10-07

A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)

Phase 1 Completed

61 enrolled 23 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02450656 2018-08-27

M14AFS

Phase 1/2 Unknown

320 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02025114 2018-07-10

Selumetinib in Combination With Gefitinib in NSCLC Patients

Phase 1/2 Completed

34 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03004105 2018-03-16

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung